Edgewise Therapeutics, Inc. financial data

Symbol
EWTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
1715 38 Th St, Boulder, CO
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.8K % +28.6%
Debt-to-equity 4.51 % -26.2%
Return On Equity -26.8 % +4.21%
Return On Assets -25.7 % +2.73%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 94.7M shares +49.2%
Common Stock, Shares, Outstanding 94.4M shares +48.8%
Entity Public Float 386M USD +55.7%
Common Stock, Value, Issued 9K USD +50%
Weighted Average Number of Shares Outstanding, Basic 93.8M shares +47.8%
Weighted Average Number of Shares Outstanding, Diluted 93.8M shares +47.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 118M USD +48.2%
General and Administrative Expense 28.9M USD +27%
Operating Income (Loss) -147M USD -43.5%
Net Income (Loss) Attributable to Parent -124M USD -39%
Earnings Per Share, Basic -1.49 USD/shares -5.67%
Earnings Per Share, Diluted -1.49 USD/shares -5.67%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 44.8M USD +36%
Assets, Current 499M USD +67.6%
Property, Plant and Equipment, Net 9.97M USD -6.68%
Operating Lease, Right-of-Use Asset 1.62M USD -29.6%
Other Assets, Noncurrent 262K USD -43.9%
Assets 511M USD +64.2%
Accounts Payable, Current 5.65M USD +6.22%
Employee-related Liabilities, Current 6.19M USD +40.3%
Accrued Liabilities, Current 6.13M USD +7.92%
Liabilities, Current 19M USD +16%
Operating Lease, Liability, Noncurrent 3.45M USD -25%
Other Liabilities, Noncurrent 192K USD
Liabilities 22.4M USD +7.01%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.05M USD
Retained Earnings (Accumulated Deficit) -339M USD -57.9%
Stockholders' Equity Attributable to Parent 489M USD +68.3%
Liabilities and Equity 511M USD +64.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -28.6M USD -25.3%
Net Cash Provided by (Used in) Financing Activities 241M USD
Net Cash Provided by (Used in) Investing Activities -268M USD -647%
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 94.4M shares +48.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -55.8M USD -313%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 44.8M USD +36%
Deferred Tax Assets, Valuation Allowance 69.6M USD +74.2%
Deferred Tax Assets, Gross 69.6M USD +74.2%
Operating Lease, Liability 2.2M USD
Depreciation 2.03M USD +87.9%
Payments to Acquire Property, Plant, and Equipment 297K USD -93.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -123M USD -40.1%
Lessee, Operating Lease, Liability, to be Paid 3.3M USD
Property, Plant and Equipment, Gross 14.1M USD +9.85%
Operating Lease, Liability, Current 992K USD +6.55%
Lessee, Operating Lease, Liability, to be Paid, Year Two 328K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 777K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 446K USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 200M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 457K USD
Additional Paid in Capital 827M USD +63.6%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 22.1M USD +37.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%